$195.58
4.55% yesterday
NYSE, Sep 18, 10:00 pm CET
ISIN
US70975L1070
Symbol
PEN
Sector

Penumbra, Inc. Stock price

$195.58
+4.13 2.16% 1M
-38.78 16.55% 6M
-55.96 22.25% YTD
-66.67 25.42% 1Y
-82.10 29.57% 3Y
+45.50 30.32% 5Y
+154.28 373.56% 10Y
NYSE, Closing price Wed, Sep 18 2024
+8.52 4.55%
ISIN
US70975L1070
Symbol
PEN
Sector

Key metrics

Market capitalization $7.60b
Enterprise Value $7.49b
P/E (TTM) P/E ratio 571.20
EV/FCF (TTM) EV/FCF 67.64
EV/Sales (TTM) EV/Sales 6.60
P/S ratio (TTM) P/S ratio 6.70
P/B ratio (TTM) P/B ratio 6.54
Revenue growth (TTM) Revenue growth 20.89%
Revenue (TTM) Revenue $1.13b
EBIT (operating result TTM) EBIT $73.95m
Free Cash Flow (TTM) Free Cash Flow $110.67m
Cash position $339.70m
EPS (TTM) EPS $0.34
P/E forward 560.80
P/S forward 6.39
EV/Sales forward 6.30
Short interest 8.77%
Show more

Is Penumbra, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Penumbra, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a Penumbra, Inc. forecast:

13x Buy
68%
6x Hold
32%

Analyst Opinions

19 Analysts have issued a Penumbra, Inc. forecast:

Buy
68%
Hold
32%

Financial data from Penumbra, Inc.

Jun '24
+/-
%
Net Profit -60 -60
418% 418%
-20%
Depreciation and Amortization 7.65 7.65
14% 14%
3%
Stock Compensation 9.56 9.56
25% 25%
3%
Operating Cash Flow 23 23
32% 32%
8%
Investments 4.54 4.54
5% 5%
2%
Dividend Paid - -
-
-
Free Cash Flow 18 18
42% 42%
6%

In millions USD.

Don't miss a Thing! We will send you all news about Penumbra, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Penumbra, Inc. Stock News

Positive
The Motley Fool
about 3 hours ago
A researcher initiated coverage of the medical device maker with a confident buy recommendation. He sees multiple positive factors that should propel its growth.
Neutral
PRNewsWire
3 days ago
Latest computer assisted vacuum thrombectomy (CAVT) technologies combine superior catheter design with the latest dual clot detection computer algorithms designed to restore blood flow quickly Lightning Flash™ 2.0 will be the most advanced thrombectomy system on the European market to address venous and pulmonary thrombus Lightning Bolt™ 7 is designed to enhance the ability to rapidly remove bl...
Neutral
PRNewsWire
22 days ago
ALAMEDA, Calif. , Aug. 27, 2024 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN) today announced that its management team is scheduled to present at the Baird Global Healthcare Conference on Tuesday, September 10, 2024.
More Penumbra, Inc. News

Company Profile

Penumbra, Inc. engages in the design, development, manufacture, and marketing of innovative medical devices. It offers thrombectomy, embolization, access, neurosurgical tools, ruby coil system, lantern, penumbra occlusion device (POD) system, packing coil, and indigo systems products. Its target markets include interventional neuroradiologists, neurosurgeons, and interventional neurologists; and interventional radiologists, vascular surgeons, and interventional cardiologists. The company was founded by Arani Bose and Adam Elsesser on June 21, 2004 and is headquartered in Alameda, CA.

Head office United States
CEO Adam Elsesser
Employees 4,200
Founded 2004
Website www.penumbrainc.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today